Evidence-Based Reviews

Opioid use disorder during pregnancy

Current Psychiatry. 2011 March;10(3):35-46

Nonjudgmental identification and treatment can maximize maternal/fetal outcomes

References

1. Flavin J, Paltrow LM. Punishing pregnant drug-using women: defying law medicine, and common sense. J Addict Dis. 2010;29(2):231-244.

2. American Psychiatric Association. Opioid use disorder. DSM-5 development. Available at: http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=460#. Accessed January 26 2011.

3. Pichini S, Puig C, Zuccaro P, et al. Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the “Meconium Project. “ Forensic Sci Int. 2005;153:59-65.

4. Mitchell JL, Brown G. Physiological effects of cocaine heroin, and methadone. In: Engs RC, ed. Women: alcohol and other drugs. Dubuque, IA: Kendall/Hunt Publishing Co; 1990:53-60.

5. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction during pregnancy. In: Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment Improvement Protocol (TIP) Series 43. Rockville MD: Substance Abuse and Mental Health Services Administration; 2005, reprinted 2006. DHHS Publication No. (SMA) 06-4212.

6. Helmbrecht GD, Thiagarajah S. Management of addiction disorders in pregnancy. J Addict Med. 2008;2(1):1-16.

7. Chasnoff If, Neuman MA, Thornton C, et al. Screening for substance abuse in pregnancy: a practical approach for the primary care physician. Am J Obstet Gynecol. 2001;184(4):752-758.

8. Chasnoff IJ, Wells AM, McGourty RF, et al. Validation of the 4P’s Plus screen for substance use in pregnancy validation of the 4P’s Plus. J Perinatol. 2007;27:744-748.

9. Jones HE. The challenges of screening for substance use in pregnant women: commentary on the 4P’s Plus tool. J Perinatol. 2005;25:365-367.

10. Center for Substance Abuse Treatment. Substance abuse treatment: addressing the specific needs of women. Treatment Improvement Protocol (TIP) Series 51. Rockville MD: Substance Abuse and Mental Health Services Administration; 2009. HHS Publication No. (SMA) 09-4426.

11. Christmas JT, Knisely JS, Dawson KS, et al. Comparison of questionnaire screening and urine toxicology for detection of pregnancy complicated by substance use. Obstet Gynecol. 1992;80:750-754.

12. Wunsch MJ, Weaver MF. Alcohol and other drug use during pregnancy: management of the mother and child. In: Ries RK Fiellin DA, Miller SC, et al, eds. Principles of addiction medicine, 4^th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2009:1111-1124.

13. Ondersma SJ, Winhusen T, Erickson SJ, et al. Motivation enhancement therapy with pregnant substance-abusing women: does baseline motivation moderate efficacy? Drug Alcohol Depend. 2009;101(1-2):74-79.

14. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin North Am. 1998;25:139-151.

15. Comfort M, Zanis DA, Whiteley MJ, et al. Assessing the needs of substance abusing women. Psychometric data on the psychosocial history. J Subst Abuse Treat. 1999;17:79-83.

16. Kissin WB, Svikis DS, Moylan P, et al. Identifying pregnant women at risk for early attrition from substance abuse treatment. J Subst Abuse Treat. 2004;27:31-38.

17. Jones HE, O’Grady KE, Malfi D, et al. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17(5):372-386.

18. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat. 2003;24(4):363-367.

19. Vesga-Lopez O, Blanco C, Keyes K, et al. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65(7):805-815.

20. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid dependent pregnant women: clinical and research issues. J Subst Abuse Treat. 2008;35(3):245-259.

21. NIDA International Program. National Institute on Drug Abuse. Methadone research web guide. Available at: http://international.drugabuse.gov/collaboration/guide_methadone/index.html. Accessed December 2, 2010.

22. Wittmann BK, Segal S. A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation. Int J Addict. 1991;26:213-218.

23. DePetrillo PB, Rice JM. Methadone dosing and pregnancy: impact on program compliance. Int J Addict. 1995;30:207-217.

24. Jansson LM, Dipietro JA, Velez M, et al. Maternal methadone dosing schedule and fetal neurobehaviour. J Matern Fetal Neonatal Med. 2009;22(1):29-35.

25. Center for Substance Abuse Treatment. Special populations: pregnant women and neonates. In: Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. Rockville MD: Substance Abuse and Mental Health Services Administration; 2004. DHHS Publication No. (SMA) 04-3939.

26. Jones HE, Johnson RE, Jasinski DR, et al. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend. 2005;78(1):33-38.

27. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients; effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1):1-10.

28. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331.

29. Nanovskaya T, Deshmukh S, Brooks M, et al. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther. 2002;300(1):26-33.

30. Svikis DS, Golden AS, Huggins GR, et al. Cost-effectiveness of treatment for drug-abusing pregnant women. Drug Alcohol Depend. 1997;45:105-113.

31. Jones HE, O’Grady K, Dahne J, et al. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug Alcohol Abuse. 2009;35(3):151-156.

Discuss this article at http://currentpsychiatry.blogspot.com/2011/03/opioid-use-disorder-during-pregnancy.html#comments

For 3 years, your mental health clinic has been treating Ms. J, age 23, for bipolar disorder. She is single, unemployed, lives alone, and receives Social Security disability assistance and financial support from her parents. She has been successfully maintained on aripiprazole, 15 mg/d, and citalopram, 20 mg/d, for 18 months. Six months ago she began to miss therapy sessions and physician visits.

Her parents inform Ms. J’s therapist that she is “snorting oxycontin” with her new boyfriend. At her next visit Ms. J confirms she has been struggling to manage an opioid use disorder for more than 1 year, and requests help.

After you educate her about the diagnosis, pathophysiology, and treatment of opioid addiction, she chooses to include pharmacotherapy as part of her treatment. After informed consent, Ms. J agrees to take buprenorphine and naloxone, meet with her therapist weekly, and attend twice-weekly Narcotics Anonymous (NA) meetings. Over the ensuing months she is gradually inducted onto buprenorphine and naloxone, 12 mg, shows improved insight and motivation, provides negative urine drug screens, and demonstrates increased ability to manage her recovery. Two weeks later Ms. J tells you she may be pregnant but wants to continue buprenorphine and naloxone.

Clinical Point

During screening, a nonjudgmental, empathic attitude may be more important than the specific questions you ask

Opioid use disorder (OUD) during pregnancy is among the most difficult clinical scenarios to manage. The prevalence of OUD during pregnancy is largely unknown. However, stigma against pregnant patients with OUD is substantial.¹ This article briefly summarizes identification, assessment, and treatment of OUD during pregnancy. To avoid confusion with the term “physical dependence, “ we will use “opioid use disorder” instead of “opioid dependence. “ The DSM-5 Substance Use Disorders Workgroup recommends combining abuse and dependence into a single disorder of graded clinical severity; however, this has not been finalized.²

Early identification is crucial

Early identification of OUD in pregnant women can be challenging. Self-reports underestimate use³ and shame, fear of prosecution or involvement of child welfare services, and guilt can further erode self-report. Women with OUD may have irregular menses and might not be aware of their pregnancy until several months after conception.⁴ Also, women with OUD who are maintained on opioid agonist therapies may misinterpret early signs of pregnancy—such as fatigue, nausea, vomiting, headaches, and cramps—as withdrawal symptoms and may respond by increasing their opioid dosing, thus exposing their fetus to increased drug levels. Finally, many women with OUD experience amenorrhea as a result of their stressful, unhealthy lifestyle, which may preclude pregnancy despite sexual activity. When these women later enroll in an opioid maintenance program, their endocrine function may return to normal, leading to unexpected pregnancy.⁵

Screening for OUD in pregnant patients has not been well studied. An interviewer’s nonjudgmental, empathic attitude may be more important than the specific questions he or she asks. It may be best to begin with less threatening questions and proceed to more specific questions after developing a therapeutic alliance.⁶

Chasnoff et al⁷ studied >2, 000 Medicaid-eligible pregnant patients from 9 prenatal clinics to identify risk factors for substance use during pregnancy. Alcohol or tobacco use in the month before pregnancy most differentiated current drug or alcohol use from nonuse while pregnant; however, a wide variation in use rates among patients in this study limits the generalizability of these findings. Consider OUD in women with:

physical examination findings or history that suggests substance use or withdrawal symptoms
positive drug test results for illicit or nonprescribed opioids
aberrant medication-taking behaviors in those receiving prescribed opioids
nicotine or alcohol use in the month before they knew they were pregnant
a history of addiction-related disorders
evidence of diseases associated with drug use, such as human immunodeficiency virus or hepatitis C
poor prenatal care attendance
unexplained fetal growth abnormalities.

Chasnoff et al demonstrated the reliability and effectiveness of a 1-minute, 5-item instrument (the “4 P’s Plus”) to screen for substance use, including heroin, during pregnancy ( Table 1 )⁸ In a study of 228 pregnant women, the overall internal consistency of this instrument was low but acceptable. More than three-quarters of patients (78%) were correctly classified as positive or negative, sensitivity was 87%, specificity was 76%, negative predictive validity was extremely high (97%), and positive predictive validity was low (36%). This low positive predictive validity may be acceptable in this population because over-identification of women at risk may be preferred to under-identification. The 4 P’s Plus identifies light and infrequent substance users who otherwise would go undetected, although it may place undue burden on providers to follow up on what later may be revealed to be a false positive screen.